Completed PHASE3 INTERVENTIONAL NCT00145002

A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)

Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.

Sponsor: Japan Clinical Oncology Group

Conditions Adult T-cell Leukemia Lymphoma

Interventions VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis biweekly-CHOP with G-CSF and intrathecal prophylaxis

Updated 6 times since 2017 Last updated: Sep 20, 2016 Started: Aug 31, 1998 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Adult T-cell Leukemia and Lymphoma and is currently completed. Japan Clinical Oncology Group leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Data source: Japan Clinical Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nagasaki, Japan